Drug maker GlaxoSmithKline (GSK) said on Tuesday it hoped to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease.
A new vaccine that has raised hopes of becoming a potent new tool in the battle against malaria seems to stop working in children after four years, according to research published Wednesday.
